HLA Class Ib-receptor interactions during embryo implantation and early pregnancy. 2022

Line Lynge Nilsson, and Thomas Vauvert F Hviid
Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), The ReproHealth Research Consortium ZUH, Zealand University Hospital, Roskilde, Denmark.

Although the immune system intuitively must have an important role in embryo implantation and in the achievement of a pregnancy, the molecular details have for long been controversial. The role of the human leukocyte antigen (HLA) system has been debated. The unique HLA expression profile of the HLA Class Ia molecule HLA-C and the HLA Class Ib molecules HLA-E, HLA-F and HLA-G at the feto-maternal interface is now recognized. However, HLA Class Ib molecules may also have a role in embryo implantation and pregnancy success. The aim of this review was to evaluate the literature and recent discoveries on the role of the non-polymorphic HLA Class Ib molecules with a focus on HLA-F and HLA-G molecules at the time of implantation, including the interaction with uterine immune cells through the specific receptors immunoglobulin-like transcript 2 (ILT2), ILT4 and a number of killer cell immunoglobulin-like receptors (KIRs), and the importance of HLA-F and HLA-G genetic variation that influences fertility and time-to-pregnancy. Drawing on recent advances in basic and clinical studies, we performed a narrative review of the scientific literature to provide a timely update on the role of HLA Class Ib in embryo implantation, fertility and infertility. Pertinent studies were searched in PubMed/Medline using relevant key words. Both HLA-F and HLA-G interact with inhibitory or activating ILT2 or ILT4 receptors and KIRs on uterine immune cells, especially uterine natural killer (NK) cells that are highly abundant in the mid-secretory endometrium and in early pregnancy. The binding of HLA-G to ILT2 stimulates the secretion of growth-promoting factors from decidual NK cells. However, functional aspects of a HLA-F-receptor interaction remain to be clarified. Recent studies indicate that HLA-F and HLA-G are expressed in mid-secretory endometrium and HLA-G is expressed in the blastocyst. HLA-F fluctuates during the menstrual cycle with high levels during the implantation window. The level of HLA-F protein expression correlates with the number of CD56-positive NK cells in the mid-secretory endometrium. HLA-F and HLA-G gene polymorphisms, including a single nucleotide polymorphism (SNP) in a progesterone-responsive element, are associated with time-to-pregnancy. Depending on the SNP genotype, the effect of progesterone varies resulting in differences in HLA-F expression and thereby the interaction with receptors on the uterine NK cells. Studies suggest that the expression of HLA-G and HLA-F, both by the embryonic-derived trophoblast cells and by cells in the endometrium and decidua, and the interaction between HLA-G and HLA-F with specific receptors on uterine immune cells, stimulate and facilitate embryo implantation and placentation by secretion of growth factors, cytokines and angiogenic factors. A detailed understanding of the molecular mechanisms controlling the expression of HLA-F and HLA-G periconceptionally and in early pregnancy may improve the success of ART and holds promise for further insight into pathophysiological aspects of certain pregnancy complications.

UI MeSH Term Description Entries
D010064 Embryo Implantation Endometrial implantation of EMBRYO, MAMMALIAN at the BLASTOCYST stage. Blastocyst Implantation,Decidual Cell Reaction,Implantation, Blastocyst,Nidation,Ovum Implantation,Blastocyst Implantations,Decidual Cell Reactions,Embryo Implantations,Implantation, Embryo,Implantation, Ovum,Implantations, Blastocyst,Implantations, Embryo,Implantations, Ovum,Nidations,Ovum Implantations
D010929 Placentation The development of the PLACENTA, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and FETUS. The process begins at FERTILIZATION, through the development of CYTOTROPHOBLASTS and SYNCYTIOTROPHOBLASTS, the formation of CHORIONIC VILLI, to the progressive increase in BLOOD VESSELS to support the growing fetus. Hemochorial Placental Development,Hemochorial Placentation,Placental Development,Placental Development, Hemochorial,Placentation, Hemochorial
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D054340 Receptors, KIR A family of receptors found on NK CELLS that have specificity for a variety of HLA ANTIGENS. KIR receptors contain up to three different extracellular immunoglobulin-like domains referred to as D0, D1, and D2 and play an important role in blocking NK cell activation against cells expressing the appropriate HLA antigens thus preventing cell lysis. Although they are often referred to as being inhibitory receptors, a subset of KIR receptors may also play an activating role in NK cells. KIR Family Receptors,KIR Receptors,Killer Inhibitory Receptors,KIR Receptor,Killer Cell Immunoglobulin-Like Receptor,Killer Cell Immunoglobulin-Like Receptors,Killer Immunoglobulin-Like Receptor,Killer Immunoglobulin-Like Receptor (KIR) Family of Receptors,Killer Inhibitory Receptor,Receptor, Killer Inhibitory,Receptor, p58 NK Cell,p58 NK Cell Inhibitory Receptor,p58 NK Cell Receptor,p58 NK Cell Receptors,p58 Natural Killer Cell Receptor,Family Receptors, KIR,Immunoglobulin-Like Receptor, Killer,Inhibitory Receptor, Killer,Inhibitory Receptors, Killer,Killer Cell Immunoglobulin Like Receptor,Killer Cell Immunoglobulin Like Receptors,Killer Immunoglobulin Like Receptor,Receptor, KIR,Receptor, Killer Immunoglobulin-Like,Receptors, KIR Family,Receptors, Killer Inhibitory
D059951 HLA-G Antigens Class I human histocompatibility (HLA) surface antigens encoded by alleles on locus B of the HLA complex. The HLA-G antigens are considered non-classical class I antigens due to their distinct tissue distribution which differs from HLA-A; HLA-B; and HLA-C antigens. Note that several isoforms of HLA-G antigens result from alternative splicing of messenger RNAs produced from the HLA-G*01 allele. HLA G,HLA-G,HLA-G Antigen,HLA-G1,HLA-G1 Isoform,HLA-G2,HLA-G2 Isoform,HLA-G3,HLA-G3 Isoform,HLA-G4,HLA-G4 Isoform,HLA-G5,HLA-G5 Isoform,HLA-G6,HLA-G6 Isoform,HLA-G7,HLA-G7 Antigen,HLA-G7 Isoform,Antigen, HLA-G,Antigen, HLA-G7,Antigens, HLA-G,HLA G Antigen,HLA G Antigens,HLA G1 Isoform,HLA G2 Isoform,HLA G3 Isoform,HLA G6 Isoform,HLA G7 Antigen,HLA G7 Isoform,Isoform, HLA-G4,Isoform, HLA-G6,Isoform, HLA-G7

Related Publications

Line Lynge Nilsson, and Thomas Vauvert F Hviid
January 2016, Frontiers in bioscience (Scholar edition),
Line Lynge Nilsson, and Thomas Vauvert F Hviid
January 2014, Frontiers in immunology,
Line Lynge Nilsson, and Thomas Vauvert F Hviid
April 2020, Journal of molecular medicine (Berlin, Germany),
Line Lynge Nilsson, and Thomas Vauvert F Hviid
May 2024, Science China. Life sciences,
Line Lynge Nilsson, and Thomas Vauvert F Hviid
January 2012, Human reproduction update,
Line Lynge Nilsson, and Thomas Vauvert F Hviid
January 1988, Reproduction, nutrition, developpement,
Line Lynge Nilsson, and Thomas Vauvert F Hviid
January 2017, Journal of cell science,
Line Lynge Nilsson, and Thomas Vauvert F Hviid
January 2002, Trends in endocrinology and metabolism: TEM,
Copied contents to your clipboard!